Education
About Us
Working with TipRanks
Follow Us
Kamada (IL:KMDA)
:KMDA
KMDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,887.99 - 2,960.32
Previous CloseN/A
Volume698.59K
Average Volume (3M)40.24K
Market Cap
$1.35B
Enterprise Value1.33B
Total Cash (Recent Filing)$65.98M
Total Debt (Recent Filing)$11.41M
Price to Earnings (P/E)19.5
Beta0.84
Next Earnings
Nov 12, 2025EPS Estimate
31.11Last Dividend Ex-Date
Mar 17, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)44.63
Shares Outstanding57,505,030
10 Day Avg. Volume36,298
30 Day Avg. Volume40,244
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue7.82
Enterprise Value/Gross Profit17.92
Enterprise Value/Ebitda38.74
Forecast
1Y Price Target
$4,350.12Price Target Upside82.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKamada reported financial results above expectations, with 2Q25 revenues of $44.8 million, up 5% compared to a year ago, and earnings per share of $0.13 versus $0.08 in the prior year.
Revenue GrowthKamada's revenue growth was driven by increased sales of Glassia outside of the US and Varizig in the US, along with distribution sales and royalty income.
Strategic InitiativesKamada is strengthening its biosimilar portfolio, expected to yield significant revenue over the next five years, further diversifying its commercial offerings.
Bears Say
AAT ProgramThere are questions regarding Kamada's AAT program, with historical challenges in delivering AAT to the lungs and concerns about whether it falls under the company's core competencies.
Gross MarginsGross margins for the quarter dipped to 42% from 45% in the prior year period, due primarily to product mix and a higher reliance on distributed product sales.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was 1887.99 and its highest was 2960.32 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $1.35B.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Nov 12, 2025 which is in 64 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Aug 13, 2025. The company reported 44.63 earnings per share for the quarter, beating the consensus estimate of 30.429 by 14.2.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of 71.008 which represents an annual dividend yield of N/A. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 31.11.
How many shares outstanding does Kamada have?
Kamada has 57,505,030 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of 44.63 in its last earnings report, beating expectations of 30.429. Following the earnings report the stock price went up 0.87%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in IL:KMDA
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4,350.12 (82.17% Upside)
$4,350.12 (82.17% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.55%
12-Months-Change
Fundamentals
Return on Equity
7.44%
Trailing 12-Months
Asset Growth
4.88%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Kamada with strong revenue and EBITDA growth, increased financial guidance, and successful strategic initiatives such as biosimilar launches and plasma center expansion. However, challenges like the decrease in gross profit margin and tax rate fluctuations present areas to monitor.View all IL:KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
4,350.12
▲(82.17% Upside)